The advent of anti-tumor necrosis factor (anti-TNF) agents has revolutionized the treatment of inflammatory bowel disease (IBD), which comprises ulcerative colitis (UC) and Crohn’s disease (CD). The gene discussed is TNF; the disease is ulcerative colitis.